Biotherapeutic Drug Discovery Project Awards
About this scheme
This scheme funds translational research projects at all stages of drug discovery, from target and pathway identification and validation, through to early preclinical studies. Awards can support early stage translational research with a clear pathway towards further biotherapeutic development.
Examples of eligible studies are:
- Validation of a novel target or pathway as a potential biotherapeutic drug target
- The generation and pre-clinical testing of new biotherapeutic drug candidates
- Re-positioning clinically validated biotherapeutic drugs in new oncology indications
- Validation of novel combinations of biotherapeutic drugs or combinations of biotherapeutics with small molecule drugs (or other therapeutic modalities) in oncology indications
- Application of novel technologies to improve the efficacy of biotherapeutic drugs
This scheme does not fund preclinical development studies required for the initiation of clinical studies, including bulk synthesis/manufacture to GMP or toxicology to GCP.
Eligible biotherapeutics include, but are not limited to:
- Therapeutic antibodies
- Cell based therapies
- Viral therapies
- Protein therapies
- Gene therapies
Applications are accepted from scientists, clinicians or health care workers in UK universities, medical schools, hospitals and some research institutions. We are willing to support collaborative projects between academic and a commercial partners if appropriate.
Please contact Marjolein Schaap in order to discuss your proposal and open an application through eGMS.
Awards typically fund up to £100,000 per annum for up to 3 years, covering:
- Salaries of postdoctoral researchers and clinical or technical staff with associated running expenses
- Equipment up to £15,000 if specifically required for the project
* If your proposed project timeline falls outside of this range or the sum you wish to apply for is significantly greater than £100,000 per annum, please contact the office to discuss your proposal before starting an application.
CRUK-MedImmune Alliance Laboratory
Successful applicants will also have the opportunity to access the CRUK-MedImmune Alliance Laboratory (CMAL). CMAL provides access to MedImmune’s proprietary phage display library, and can support antibody production. Applicants wishing to access the CMAL should include this in their application.
If you are already a CRUK-funded scientist, you can apply directly to access the CMAL.
How to apply to this scheme
Applications are considered twice a year and follow a two-stage process:
- Outline application: you must submit a four page outline application, which will be reviewed by the Biotherapeutic Expert Review Panel (BTERP) prior to being invited to submit a full application
- Full application: if your outline application is successful you will be invited to submit a full application. All applicants will have an interview with the BTERP
Outline application deadline
Full application deadline
May 2017 Drug Discovery Committee
7 November 2016
Late March to early April 2017
November 2017 Drug Discovery Committee
23 May 2017
17 August 2017
02-03 October 2017
Before you begin your application
- You must read the application guidelines (PDF 959KB) and grant conditions (PDF 448KB)
- You must read the Costs Guidance to understand what costs can be included in the award
- The full application must be approved by your host institution.
All applications must be made through our electronic Grants Management System (eGMS). Please contact Marjolein Schaap in order to discuss your proposal and open an application through eGMS. Outline applications will be open from 03 April 2017.
Applications are assessed on their potential to develop a new preventative or therapeutic approach – the outputs of funded research should provide information that will significantly contribute to the development and eventual clinical testing of a medicine to deliver on an unmet medical need in oncology.
Applications should include a project plan that charts a route to develop the findings, including specific achievable milestones and endpoints.
To support our investigator-led drug discovery research we have made extensive investment in infrastructure for biotherapeutic and small molecule drug discovery.
More funding schemes like this
We're driving discovery research in immuno-oncology which is leading to novel and exciting immunotherapeutic possibilities.